Ruthenium-peptide conjugates: arrows for selectively targeting breast cancer
Arrows2cancer aims to contribute to the chemotherapy field through the development of an innovative and precise chemotherapeutic for triple negative breast cancer. In particular, Arrows2cancer aims to overcome the limitations of the current drugs in clinical use by developing smart drug delivery systems (SDDSs) of ruthenium selectively to primary tumors and metastases of triple negative breast cancer. The structure of these SDDSs focuses on the differences between cancerous and healthy cells to introduce functional groups sensitive to a variety of tumor environment stimuli to achieve an optimization of the therapeutic efficiency of the ruthenium drug through its controlled release and more efficient delivery to the target.
March, 2021 - February, 2024